An official website of the United States government.
Date posted
Funding Agency
(Funded by the U.S. National Science Foundation and the National Institutes of Health)
A few years ago, researchers at Carnegie Mellon University made an intriguing discovery: adding a branch to the end of lipid nanoparticles' normally linear lipid tails dramatically improved messenger RNA (mRNA) delivery. Now, researchers at the University of Pennsylvania have tested branched lipids in a variety of experiments and found that these lipids reliably outperform even the lipid nanoparticles used by Moderna and Pfizer/BioNTech, the makers of the COVID-19 vaccines. The researchers hope the branched lipids will not only improve lipid nanoparticle delivery but also inspire a new approach to designing lipids, moving away from trial-and-error methods.
Keywords
